Explore the Agenda
Morning Keynote Plenary Session
7:15 am Check-In & Morning Coffee
8:15 am Honorary Opening Remarks
Blazing the Way for TPD Into 2026: Insights on Clinical Differentiation, Modality Leadership & Entrepreneurial Growth to Continue Making Strides in a Competitive Therapeutic Landscape
8:30 am CXO Think Tank: How Can TPD Differentiate Itself in a Maturing Market of Targeted Drugs & Enter the Standard of Care to Deliver Transformative Therapies to Oncology Patients & Beyond
9:15 am Panel Discussion: From Bench to Business: Entrepreneurial Journeys in Induced Proximity Therapeutics
9:45 am Charting New Frontiers in Targeted Protein Degradation for Oncology & Neurodegenerative Indications
10:15 am Fireside Chat: Discussing TPD’s Position in the Hematological Oncology Space, Combination Strategies & the Path to the Standard of Care
10:45 am Morning Break & Speed Networking
With an international gathering of TPD and Induced Proximity experts, this valuable session will ensure you can connect with your peers in the room to make new and lasting connections. All attendees will have the opportunity to meet and network with their academic and industry colleagues!
Track A: Discovery
Track A: Discovery – Showcasing the Next Generation of TPD & Induced Proximity Platforms Accelerating Discovery Efforts Against High-Value Targets Chair: Lingling Shen, Associate Director of Data Sciences, Novartis
11:45 am Harnessing Non-Degrading Molecular Glues to Target Undruggable Proteins
SVP, Research, Magnet Biomedicine
12:15 pm From Binary to Ternary Complexes: Applying Spectral Shift to Reveal PROTAC Parameters in E3 Ligase-Targeted Systems
CSO, Trilogie Bioscience
Senior Application Scientist, NanoTemper Technologies
Track B: Pre-Clinical Development
Track C: Translational & Clinical Development
12:45 pm Lunch Break
Track A: Discovery
Supercharging Precision with Degrader-Antibody Conjugates & Smarter Discovery Workflows to De-Risk Induced Proximity Therapeutics
2:00 pm Advancing DACs for Precision Oncology with SMARCA2/4 & CDK9 Targeted Degrader Payloads
Senior Director - Biology, Prelude Therapeutics
2:30 pm Rapid Identification, Validation, & Optimization of Novel Degraders Through Integrated High-Throughput Proteomics
Chief Scientific Officer, NEOsphere Biotechnologies GmbH
3:00 pm Panel Discussion: Overcoming the Common Pitfalls in Early Workflows for the Discovery of Induced Proximity Drugs
Vice President of Lead Discovery, C4 Therapeutics
CEO, Founder, Birdwood Therapeutics
Executive Vice President - Discovery Science, Parabilis Medicines
Director - Biophysics, High Throughput Screening & Oncology, Pfizer
Track B: Pre-Clinical Development
Track C: Translational & Clinical Development
3:30 pm Afternoon Break & Poster Session
Track A: Discovery
Driving Advanced Library Construction & Structural Modeling to Optimize Ternary Complex Kinetics for Enhanced Therapeutic Effects
4:30 pm Non-Degrading Molecular Glues: A Platform for Finding Novel Chemical Matter for Inhibiting Intracellular & Transmembrane Proteins
Senior Director, Sciences Head of Platform, Rapafusyn Pharmaceuticals
5:00 pm From Disappearance to Mechanism: Degradation First Validation with CETSA® & Proteome Wide Profiling
CEO, Pelago Bioscience
5:30 pm Precision Degradation of Tau: PROTACs Target Phosphorylated Tau in Various Alzheimer’s Disease Models
Associate Director of Discovery, Strategy & Business Development, SAI Life Sciences Ltd
5:40 pm Chair’s Closing Remarks
Director - Biophysics, High Throughput Screening & Oncology, Pfizer
Track B: Pre-Clinical Development
Track C: Translational & Clinical Development